Cargando…

Evaluation of the Drug–Drug Interaction Potential of Ensitrelvir Fumaric Acid with Cytochrome P450 3A Substrates in Healthy Japanese Adults

BACKGROUND: Management of drug–drug interactions (DDIs) for ensitrelvir, a novel 3-chymotrypsin-like protease inhibitor of SARS-CoV-2 infection is crucial. A previous clinical DDI study of ensitrelvir with midazolam, a clinical index cytochrome P450 (CYP) 3A substrate, demonstrated that ensitrelvir...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shimizu, Ryosuke, Sonoyama, Takuhiro, Fukuhara, Takahiro, Kuwata, Aya, Matsuzaki, Takanobu, Matsuo, Yumiko, Kubota, Ryuji
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2023
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10177727/ https://www.ncbi.nlm.nih.gov/pubmed/37171749 http://dx.doi.org/10.1007/s40261-023-01265-8

Ejemplares similares

A Phase 1 Study of Ensitrelvir Fumaric Acid Tablets Evaluating the Safety, Pharmacokinetics and Food Effect in Healthy Adult Populations
por: Shimizu, Ryosuke, et al.
Publicado: (2023)

Safety, Tolerability, and Pharmacokinetics of the Novel Antiviral Agent Ensitrelvir Fumaric Acid, a SARS-CoV-2 3CL Protease Inhibitor, in Healthy Adults
por: Shimizu, Ryosuke, et al.
Publicado: (2022)

Pharmacokinetics, safety, and tolerability of single and multiple doses of zuranolone in Japanese and White healthy subjects: A phase 1 clinical trial
por: Sonoyama, Takuhiro, et al.
Publicado: (2023)

548. Combined Results of the Phase 2a/2b/3 Randomized Controlled Trials of Ensitrelvir for the Treatment of COVID-19 Infection
por: Tsuge, Yuko, et al.
Publicado: (2023)

530. Population Pharmacokinetic Analysis of Ensitrelvir, an Inhibitor of 3C-like (3CL) Protease of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) for patients with SARS-Cov-2 Infection
por: Ishibashi, Toru, et al.
Publicado: (2023)

Evaluation of Potential Drug‐Drug Interaction Risk of Pexidartinib With Substrates of Cytochrome P450 and P‐Glycoprotein
por: Zahir, Hamim, et al.
Publicado: (2020)

549. Ensitrelvir for the Treatment of COVID-19 Infection: Evaluation of Taste Disorder and Smell Disorder in the Phase 3 Part of the Phase 2/3 SCORPIO-SR Randomized Controlled Trial
por: Tsuge, Yuko, et al.
Publicado: (2023)

Role of cytochrome P450 in drug interactions
por: Bibi, Zakia
Publicado: (2008)

Efficacy and Safety of Ensitrelvir in Patients With Mild-to-Moderate Coronavirus Disease 2019: The Phase 2b Part of a Randomized, Placebo-Controlled, Phase 2/3 Study
por: Mukae, Hiroshi, et al.
Publicado: (2022)

Effects of Tenapanor on Cytochrome P450‐Mediated Drug‐Drug Interactions
por: Johansson, Susanne, et al.
Publicado: (2017)

Retraction: Role of cytochrome P450 in drug interactions
por: Bibi, Zakia
Publicado: (2014)

Cytochrome P450 Enzymes and Drug Metabolism in Humans
por: Zhao, Mingzhe, et al.
Publicado: (2021)

Cytochrome P450-Based Drug-Drug Interactions of Vonoprazan In Vitro and In Vivo
por: Wang, Yiran, et al.
Publicado: (2020)

In Silico Prediction of Drug–Drug Interactions Mediated by Cytochrome P450 Isoforms
por: Dmitriev, Alexander V., et al.
Publicado: (2021)

Deuterium isotope effects in drug pharmacokinetics II: Substrate-dependence of the reaction mechanism influences outcome for cytochrome P450 cleared drugs
por: Sun, Hao, et al.
Publicado: (2018)

Use of Drugs that Act on the Cytochrome P450 System in the Elderly
por: Cabrera, Marcos A S, et al.
Publicado: (2009)

Clinical Pharmacogenetics of Cytochrome P450-Associated Drugs in Children
por: Aka, Ida, et al.
Publicado: (2017)

A Randomized Phase 2/3 Study of Ensitrelvir, a Novel Oral SARS-CoV-2 3C-Like Protease Inhibitor, in Japanese Patients with Mild-to-Moderate COVID-19 or Asymptomatic SARS-CoV-2 Infection: Results of the Phase 2a Part
por: Mukae, Hiroshi, et al.
Publicado: (2022)

Drug-drug interaction of acetaminophen and roxithromycin with the cocktail of cytochrome P450 and hepatotoxicity in rats
por: Liu, Xiang, et al.
Publicado: (2020)

Pharmacokinetic drug interactions of asciminib with the sensitive cytochrome P450 probe substrates midazolam, warfarin, and repaglinide in healthy participants
por: Hoch, Matthias, et al.
Publicado: (2022)

Comparative Cytochrome P450 In Vitro Inhibition by Atypical Antipsychotic Drugs
por: Gervasini, Guillermo, et al.
Publicado: (2013)

An update on the role of intestinal cytochrome P450 enzymes in drug disposition
por: Xie, Fang, et al.
Publicado: (2016)

Effect of health foods on cytochrome P450-mediated drug metabolism
por: Sasaki, Takamitsu, et al.
Publicado: (2017)

A history of the roles of cytochrome P450 enzymes in the toxicity of drugs
por: Guengerich, F. Peter
Publicado: (2020)

Inflammatory signaling on cytochrome P450-mediated drug metabolism in hepatocytes
por: Wang, Xiaokang, et al.
Publicado: (2022)

Substrate binding induces structural changes in cytochrome P450cam
por: Sakurai, Keisuke, et al.
Publicado: (2009)

African Genetic Diversity: Implications for Cytochrome P450-mediated Drug Metabolism and Drug Development
por: Rajman, Iris, et al.
Publicado: (2017)

Dissecting the Cytochrome P450 OleP Substrate Specificity: Evidence for a Preferential Substrate
por: Parisi, Giacomo, et al.
Publicado: (2020)

Interaction of proton pump inhibitors with cytochromes P450: consequences for drug interactions.
por: Meyer, U. A.
Publicado: (1996)

Prediction of cytochrome P450 isoform responsible for metabolizing a drug molecule
por: Mishra, Nitish K, et al.
Publicado: (2010)

Role of cytochrome P450 genotype in the steps toward personalized drug therapy
por: Cavallari, Larisa H, et al.
Publicado: (2011)

Cytochrome P450 enzyme mediated herbal drug interactions (Part 1)
por: Wanwimolruk, Sompon, et al.
Publicado: (2014)

Cytochrome P450 enzyme mediated herbal drug interactions (Part 2)
por: Wanwimolruk, Sompon, et al.
Publicado: (2014)

Structure-Based Drug Design for Cytochrome P450 Family 1 Inhibitors
por: Dutkiewicz, Zbigniew, et al.
Publicado: (2018)

Computational methods and tools to predict cytochrome P450 metabolism for drug discovery
por: Tyzack, Jonathan D., et al.
Publicado: (2019)

Hydroxylation of Antitubercular Drug Candidate, SQ109, by Mycobacterial Cytochrome P450
por: Bukhdruker, Sergey, et al.
Publicado: (2020)

Inhibition of Cytochrome P450 Enzymes by Drugs—Molecular Basis and Practical Applications
por: Guengerich, F. Peter
Publicado: (2022)

Metabolism of 4-Aminopiperidine Drugs by Cytochrome P450s: Molecular and Quantum Mechanical Insights into Drug Design
por: Sun, Hao, et al.
Publicado: (2011)

Potential Cytochrome P450 Drug-Drug Interaction Among Adult and Adolescent Patients Undergoing Tonsillectomy
por: Nimmagadda, Sai, et al.
Publicado: (2020)

Role of residue 87 in substrate selectivity and regioselectivity of drug-metabolizing cytochrome P450 CYP102A1 M11
por: Vottero, Eduardo, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_dpegfi4cs8m723ime8sb144qc7